1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hormone Refractory Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Hormone Refractory Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hormone Refractory Breast Cancer Report is to understand the market and pipeline status of the drugs around the Hormone Refractory Breast Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hormone Refractory Breast Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Hormone Refractory Breast Cancer.
- A review of the marketed products under prescription for Hormone Refractory Breast Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hormone Refractory Breast Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hormone Refractory Breast Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hormone Refractory Breast Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hormone Refractory Breast Cancer drugs.
- Coverage of Hormone Refractory Breast Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Hormone Refractory Breast Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hormone Refractory Breast Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hormone Refractory Breast Cancer.
- API intelligence over marketed drugs forHormone Refractory Breast Cancerand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hormone Refractory Breast Cancer.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Hormone Refractory Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hormone Refractory Breast Cancer
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hormone Refractory Breast Cancer
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hormone Refractory Breast Cancer
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Hormone Refractory Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Hormone Refractory Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Hormone Refractory Breast Cancer Therapeutic Market, US, (Year), 2017
- Hormone Refractory Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Hormone Refractory Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, Europe by Country, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, India by State, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, China by Province, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers by Geography 2017
- Hormone Refractory Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Hormone Refractory Breast Cancer Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Hormone Refractory Breast Cancer, 2017
- Discontinued Drugs for Hormone Refractory Breast Cancer, 2017


List of Figures

- Hormone Refractory Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Hormone Refractory Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Hormone Refractory Breast Cancer Therapeutic Market, US, (Year), 2017
- Hormone Refractory Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Hormone Refractory Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, Europe by Country, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, India by State, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers, China by Province, 2017
- Hormone Refractory Breast Cancer Drugs, API Manufacturers by Geography 2017
- Hormone Refractory Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Hormone Refractory Breast Cancer Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Hospital Statistics in the US

  • March 2017
    16 pages
  • Hospital  

    Breast Cancer  

  • United States  

View report >

Cancer Statistics in the Netherlands

  • March 2017
    21 pages
  • Cancer  

  • Netherlands  

View report >

Cancer Statistics

18 days ago

Related Market Segments :

Breast Cancer
Cloud Computing
Hormone

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.